A business of Fujifilm Holdings (TYO: 4901) has announced it will buy USA-based recombinant protein company Shenandoah Biotechnology for an undisclosed amount.
The acquisition will be made by the conglomerate’s biotech unit, Fujifilm Irvine Scientific, which focuses on the development and manufacture of serum-free and chemically defined cell culture media.
These products are used for life sciences research, bioproduction, and cell therapy manufacturing.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze